comparemela.com
Home
Live Updates
Santhera Pharmaceuticals Holding AG: Santhera and ReveraGen Announce First Participant Dosed in FDA-funded Phase 2 Pilot Study with Vamorolone in Becker Muscular Dystrophy : comparemela.com
Santhera Pharmaceuticals Holding AG: Santhera and ReveraGen Announce First Participant Dosed in FDA-funded Phase 2 Pilot Study with Vamorolone in Becker Muscular Dystrophy
Pratteln, Switzerland, and Rockville, MD, USA, August 22, 2022 - Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce that the first patient has been dosed in a Phase 2 pilot
Related Keywords
Pratteln ,
Switzerland General ,
Switzerland ,
United States ,
United Kingdom ,
France ,
America ,
Swiss ,
Acta Myol ,
Shabir Hasham ,
Eric Hoffman ,
Eva Kalias ,
Paula Clemens ,
Reveragen Biopharma ,
Reveragen Biopharma Inc ,
Life Science Alliance ,
Santhera Pharmaceuticals ,
Muscular Dystrophy Association United States ,
University Of Pittsburgh School Medicine ,
National Institutes Of Health ,
Duchenne Research Fund ,
Foundation To Eradicate Duchenne ,
Drug Administration ,
Head Global Medical Affairs ,
Santhera Pharmaceuticals Holding ,
Head Investor Relations Communications ,
Chiesi Group ,
Us Department Of Defense ,
Chief Medical Officer ,
Pittsburgh School ,
Study Chair ,
Orphan Drug ,
Fast Track ,
Rare Pediatric Disease ,
Promising Innovative Medicine ,
Proc Natl Acad Sci United States ,
North America ,
Parent Project Muscular Dystrophy ,
Eradicate Duchenne ,
Save Our Sons ,
Action Duchenne ,
Defeat Duchenne ,
National Institutes ,
Head Investor Relations ,
Santhera ,
Pharmaceuticals ,
Molding ,
Everagen ,
Nnounce ,
First ,
Participant ,
Hosed ,
Funded ,
Hase ,
Pilot ,
Study ,
Vamorolone ,
Pecker ,
Muscular ,
Dystrophy ,
comparemela.com © 2020. All Rights Reserved.